145 related articles for article (PubMed ID: 11420933)
1. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.
Ganière JP; Médaille C; Limet A; Ruvoen N; André-Fontaine G
Vet Dermatol; 2001 Jun; 12(3):171-5. PubMed ID: 11420933
[TBL] [Abstract][Full Text] [Related]
2. Epidemiosurveillance of antimicrobial compound resistance of Staphylococcus intermedium clinical isolates from canine pyodermas.
Pellerin JL; Bourdeau P; Sebbag H; Person JM
Comp Immunol Microbiol Infect Dis; 1998 Apr; 21(2):115-33. PubMed ID: 9611682
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
[TBL] [Abstract][Full Text] [Related]
4. Determination of skin concentrations of enrofloxacin in dogs with pyoderma.
DeManuelle TC; Ihrke PJ; Brandt CM; Kass PH; Vulliet PR
Am J Vet Res; 1998 Dec; 59(12):1599-604. PubMed ID: 9858413
[TBL] [Abstract][Full Text] [Related]
5. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections.
Ganière JP; Médaille C; Etoré F
Res Vet Sci; 2004 Aug; 77(1):67-71. PubMed ID: 15120955
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial drug susceptibility of Staphylococcus intermedius clinical isolates from canine pyoderma.
Ganiere JP; Medaille C; Mangion C
J Vet Med B Infect Dis Vet Public Health; 2005 Feb; 52(1):25-31. PubMed ID: 15702997
[TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
[TBL] [Abstract][Full Text] [Related]
8. Use of enrofloxacin.
Dick GC
Vet Rec; 1993 Jun; 132(24):616. PubMed ID: 8393228
[No Abstract] [Full Text] [Related]
9. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
Brothers AM; Gibbs PS; Wooley RE
Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial.
Paradis M; Abbey L; Baker B; Coyne M; Hannigan M; Joffe D; Pukay B; Trettien A; Waisglass S; Wellington J
Vet Dermatol; 2001 Jun; 12(3):163-9. PubMed ID: 11420932
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of difloxacin against canine bacterial isolates.
van den Hoven R; Wagenaar JA; Walker RD
J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of antimicrobial-resistant staphylococci in nares and affected sites of pet dogs with superficial pyoderma.
Nakaminami H; Okamura Y; Tanaka S; Wajima T; Murayama N; Noguchi N
J Vet Med Sci; 2021 Feb; 83(2):214-219. PubMed ID: 33342967
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance of Staphylococcus pseudintermedius isolates from healthy dogs and dogs affected with pyoderma in Japan.
Onuma K; Tanabe T; Sato H
Vet Dermatol; 2012 Feb; 23(1):17-22, e5. PubMed ID: 21745248
[TBL] [Abstract][Full Text] [Related]
14. Increasing antimicrobial resistance in clinical isolates of Staphylococcus intermedius group bacteria and emergence of MRSP in the UK.
Beever L; Bond R; Graham PA; Jackson B; Lloyd DH; Loeffler A
Vet Rec; 2015 Feb; 176(7):172. PubMed ID: 25376505
[TBL] [Abstract][Full Text] [Related]
15. Frequency and antimicrobial susceptibility of Staphylococcus species isolated from canine pyodermas.
Medleau L; Long RE; Brown J; Miller WH
Am J Vet Res; 1986 Feb; 47(2):229-31. PubMed ID: 3954195
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of Fluoroquinolone- and Methicillin-resistant Staphylococcus pseudintermedius isolates from canine pyoderma and otitis externa in veterinary teaching hospital.
Yoo JH; Yoon JW; Lee SY; Park HM
J Microbiol Biotechnol; 2010 Apr; 20(4):798-802. PubMed ID: 20467256
[TBL] [Abstract][Full Text] [Related]
17. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections.
Cooke CL; Singer RS; Jang SS; Hirsh DC
J Am Vet Med Assoc; 2002 Jan; 220(2):190-2. PubMed ID: 12126128
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Staphylococcus intermedius isolated from healthy and diseased dogs.
Shimizu A; Wakita Y; Nagase S; Okabe M; Koji T; Hayashi T; Nagase N; Sasaki A; Kawano J; Yamashita K; Takagi M
J Vet Med Sci; 2001 Mar; 63(3):357-60. PubMed ID: 11307945
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal antimicrobial susceptibility trends of canine Staphylococcus pseudintermedius.
Calabro C; Sadhu R; Xu Y; Aprea M; Guarino C; Cazer CL
Prev Vet Med; 2024 May; 226():106170. PubMed ID: 38493570
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibilities of recent field isolates of Mycoplasma hyopneumoniae and Mycoplasma hyosynoviae to valnemulin (Econor), tiamulin and enrofloxacin and the in vitro development of resistance to certain antimicrobial agents in Mycoplasma hyopneumoniae.
Hannan PC; Windsor HM; Ripley PH
Res Vet Sci; 1997; 63(2):157-60. PubMed ID: 9429250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
